Surface modification of PAMAM dendrimer improves its biocompatibility

• Published in: Nanomedicine Vol. 8; no. 6; pp. 815 - 817
• Main Authors: Ciolkowski, Michal, PhD, Petersen, Johannes F., MSc, Ficker, Mario, MSc, Janaszewska, Anna, PhD, Christensen, Jørn B., Prof, Klajnert, Barbara, DSc, Bryszewska, Maria, Prof
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01-08-2012
• Subjects: Animals; Biocompatibility, Circular dichroism; Biocompatible Materials - chemical synthesis; Biocompatible Materials - pharmacology; Cell Line; Cell Survival - drug effects; Dendrimers - chemical synthesis; Dendrimers - pharmacology; Hemolysis; Internal Medicine; Materials Testing; Mice; Neurons - drug effects; Neurons - physiology; PAMAM dendrimer; Surface modification; Surface Properties; Hemolysis; Biocompatibility, Circular dichroism; Surface modification; PAMAM dendrimer
• ISSN: 1549-9634; 1549-9642
• DOI: 10.1016/j.nano.2012.03.009

Abstract Modification of dendrimer surface groups is one of the methods available to obtain compounds characterized by reduced toxicity. This article reports results of preliminary biocompatibility studies of a modified polyamidoamine dendrimer of the fourth generation. Reaction with dimethyl itaconate resulted in transformation of surface amine groups into pyrrolidone derivatives. Interaction of the modified dendrimer with human serum albumin (HSA) was analyzed. The influence of the dendrimer on mouse neuroblastoma cell line viability and its hemolytic properties were also investigated. The binding constant between analyzed dendrimer and HSA was found to be equal to 1.2 × 105 ± 0.2 × 105 M–1 . Small changes in HSA secondary structure were observed. The analyzed dendrimer revealed minor toxic activity, as diminishment in cell viability was observed only for dendrimer concentrations higher than 2 mg/mL. Moreover, under the applied experimental conditions, no hemolytic activity was observed. Those observations point to the potential of the analyzed compound for further studies toward its applicability in nanomedicine. From the Clinical Editor This basic science paper explores the biocompatibility of fourth generation surface modified PAMAM dendrimers for future preclinical applications.